Equities Analysts Set Expectations for RCUS Q1 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Arcus Biosciences in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($1.30) for the quarter. HC Wainwright has a "Neutral" rating and a $18.00 price target on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for Arcus Biosciences' Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.15) EPS and FY2029 earnings at ($1.80) EPS.

RCUS has been the subject of a number of other reports. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Arcus Biosciences in a research report on Thursday, November 7th. Morgan Stanley reduced their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday. Barclays boosted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an "overweight" rating in a research report on Friday, October 25th. Finally, Bank of America reduced their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Wednesday. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $29.50.

Arcus Biosciences Stock Performance

RCUS traded up $0.32 on Thursday, reaching $11.06. The company had a trading volume of 1,238,479 shares, compared to its average volume of 894,829. Arcus Biosciences has a 1 year low of $10.63 and a 1 year high of $20.31. The stock has a market capitalization of $1.01 billion, a PE ratio of -3.51 and a beta of 0.84. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock has a 50-day moving average price of $13.92 and a 200-day moving average price of $15.55.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Woodline Partners LP grew its position in shares of Arcus Biosciences by 1.3% in the fourth quarter. Woodline Partners LP now owns 3,523,937 shares of the company's stock valued at $52,471,000 after purchasing an additional 45,497 shares during the last quarter. Two Sigma Advisers LP boosted its position in Arcus Biosciences by 35.8% during the fourth quarter. Two Sigma Advisers LP now owns 58,800 shares of the company's stock worth $876,000 after acquiring an additional 15,500 shares during the last quarter. Two Sigma Investments LP boosted its position in Arcus Biosciences by 8.1% during the fourth quarter. Two Sigma Investments LP now owns 146,686 shares of the company's stock worth $2,184,000 after acquiring an additional 11,027 shares during the last quarter. Tema Etfs LLC acquired a new stake in Arcus Biosciences during the fourth quarter worth approximately $331,000. Finally, ProShare Advisors LLC boosted its position in Arcus Biosciences by 44.4% during the fourth quarter. ProShare Advisors LLC now owns 16,379 shares of the company's stock worth $244,000 after acquiring an additional 5,038 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the company's stock, valued at $902,070. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 12.30% of the stock is currently owned by corporate insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.